Author:
Li Pu-Chun,Zhu Yi-Fan,Cao Wen-Ming,Li Bei
Abstract
AbstractBRCA2-mutated carriers have a high lifetime risk of breast cancer (BC), an early age of onset, and an increased risk of other cancers (including ovarian, pancreatic, and prostate cancer). Almost 70–80% of BRCA2-mutated BC are estrogen receptor (ER)-positive, which is a particular type of ER-positive BC that differs from sporadic ER-positive BC. This article reviews the clinicopathological features, treatment, and prognosis of ER-positive and BRCA2-mutated BC to provide a reference for clinical decision-making.
Funder
Natural Science Foundation of Zhejiang Province
Basic Public Welfare Research Plan of Zhejiang Province
Medical and Health Science and Technology Plan Project of Zhejiang Province
Construction Fund of Key Medical Disciplines of Hangzhou
Publisher
Springer Science and Business Media LLC
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献